Search

Your search keyword '"Park, J.J."' showing total 267 results
Start Over Author "Park, J.J."
267 results on '"Park, J.J."'

1. Safety and Tolerability of Magrolimab Combination Therapy in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM-HNSCC)

Author

Colevas, A.D., primary, Kerrigan, K., additional, Chin, V., additional, Rainey, N., additional, Park, J.J., additional, Fang, B., additional, Costa, D. Alpuim, additional, Dinis, J., additional, Phan, M., additional, Lin, L., additional, Zhang, Y., additional, Sun, S.C.C., additional, Howland, M., additional, Curtis, K., additional, and Adkins, D., additional

Published
2024
Full Text
View/download PDF

5. Artificial intelligence based personalized oncological outcome prediction model for upper urinary tract urothelial carcinoma after radical nephroureterectomy: Development and multi-center validation

Author

Kim, D., primary, Nam, K.H., additional, Lee, H.Y., additional, Lim, B., additional, Kim, D., additional, Jeong, Y., additional, Jeong, I.G., additional, Park, J.J., additional, You, D., additional, Hong, J.H., additional, Song, C., additional, Ku, J.H., additional, Hong, B., additional, Ahn, H., additional, Kim, H., additional, and Suh, J., additional

Published
2024
Full Text
View/download PDF

11. 838P Patterns of response/progressive disease (PD) and management following PD with anti-PD-1 (PD1) in patients (pts) with advanced cutaneous squamous cell carcinoma (cSCC)

Author

Mo, J., primary, Bohne, A-S., additional, Gaudy Marqueste, C., additional, Della Marta, N., additional, Festino, L., additional, Chen, C., additional, Lo, S.N., additional, Park, J.J., additional, Ascierto, P.A., additional, Ladwa, R., additional, Xu, W., additional, Grob, J.J., additional, Hauschild, A., additional, Menzies, A.M., additional, Long, G.V., additional, Carlino, M.S., additional, and Pires da Silva, I., additional

Published
2022
Full Text
View/download PDF

12. P1.15-08 Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer

Author

Richardson, G.E., primary, Park, J.J., additional, Boyer, M.J., additional, Gutierrez, M., additional, Carbone, D.P., additional, Savvides, P., additional, Kaumaya, P., additional, Bekaii-Saab, T.S., additional, Phan, T.G., additional, Chong, L.M.O., additional, Cha, S., additional, Ede, N., additional, Nixon, B., additional, Withana, N.P., additional, and Good, A.J., additional

Published
2022
Full Text
View/download PDF

15. Control of reactive collisions by quantum interference

Author

Son, H., Park, J.J., Lu, Y.-K., Jamison, A.O., Karman, T., Ketterle, Wolfgang, Son, H., Park, J.J., Lu, Y.-K., Jamison, A.O., Karman, T., and Ketterle, Wolfgang

Abstract

Contains fulltext : 247554.pdf (Publisher’s version ) (Closed access)

Published
2022

16. A phase I dose-escalation and expansion study of HBM4003, an anti-CTLA-4 heavy chain only monoclonal antibody, in patients with advanced solid tumors.

Author

Gu S., De Souza P.L., Shi Y., Han W., Luo S.X., Chen J., Day D., Frentzas S., Park J.J., Shao G., Wu S., Fang M., Haydon A.M., Sun S., Lei K., Ding L., Zuo R., Gan X., Zhao Y., Chen X., Gu S., De Souza P.L., Shi Y., Han W., Luo S.X., Chen J., Day D., Frentzas S., Park J.J., Shao G., Wu S., Fang M., Haydon A.M., Sun S., Lei K., Ding L., Zuo R., Gan X., Zhao Y., and Chen X.

Abstract

Background: HBM4003 is a fully human heavy chain only monoclonal antibody (HCAb) to CTLA-4, which has been engineered to deplete Treg cells by enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. In the Phase 1 dose escalation part, HBM4003 showed favorable safety and efficacy profile in patients (pts) with advanced solid tumors. Here, we present the updated data from the dose escalation part and most recent safety and clinical activity data from three expansion cohorts of pts with advanced hepatocellular carcinoma (HCC), melanoma, and renal cell carcinoma (RCC). Method(s): In the dose-escalation part, pts were enrolled into 3 dose levels (DL): 0.3mg/kg QW (28-day cycle), 0.45mg/kg Q3W (21-day cycle), and 0.6mg/kg Q3W (21-day cycle). In the dose-expansion part, pts with advanced HCC, melanoma, and RCC received 0.45 mg/kg Q3W (21-day cycle). Tumor measurements were performed every 6 weeks for up to 12 months and subsequently every 12 weeks per RECIST v1.1. Result(s): In total 60 pts were included for this analysis, including 24 pts with advanced solid tumors in the dose escalation part and 36 pts in the dose expansion part: 18 pts with HCC, 4 pts with melanoma, and 14 pts with RCC, from 12 sites in mainland China, 5 sites in Australia, and 1 site in Hong Kong. 46 pts (77%) received >= 2 lines of previous systemic therapies and 37 pts (62%) received previous PD-1/PD-L1 treatment. For the HCC cohort, 19 pts were treated in dose-escalation (1 pt, 0.45 mg/kg Q3W) and dose-expansion parts. All 19 pts received previous PD-1/PD-L1 therapy. 12 pts were evaluable for efficacy. Two had stable disease (SD), 2 pts had partial response (PR) as best response. For 12 evaluable pts, ORR was 16.7% and disease control rate (DCR) was 33.3%. For the RCC cohort, 19 pts were treated in dose-escalation and dose-expansion parts; 18 pts were evaluable for efficacy. Eight had SD as best response; the DCR was 44.4%. Overall, the most common treatment- related adverse event (TRAE)

Published
2022

20. Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin

Author

Talukder, R. Makrakis, D. Diamantopoulos, L.N. Carril-Ajuria, L. Castellano, D. De Kouchkovsky, I. Koshkin, V.S. Park, J.J. Alva, A. Bilen, M.A. Stewart, T.F. McKay, R.R. Santos, V.S. Agarwal, N. Jain, J. Zakharia, Y. Morales-Barrera, R. Devitt, M.E. Grant, M. Lythgoe, M.P. Pinato, D.J. Nelson, A. Hoimes, C.J. Shreck, E. Gartrell, B.A. Sankin, A. Tripathi, A. Zakopoulou, R. Bamias, A. Murgic, J. Fröbe, A. Rodriguez-Vida, A. Drakaki, A. Liu, S. Kumar, V. Lorenzo, G.D. Joshi, M. Velho, P.I. Buznego, L.A. Duran, I. Moses, M. Barata, P. Sonpavde, G. Yu, E.Y. Wright, J.L. Grivas, P. Khaki, A.R.

Abstract

Background: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and without prior intravesical Bacillus Calmette-Guerin (BCG), who received ICI for aUC, hypothesizing that prior intravesical BCG would be associated with worse outcomes. Patients and Methods: We performed a retrospective cohort study across 25 institutions in US and Europe. We compared observed response rate (ORR) using logistic regression; progression-free survival (PFS) and OS using Kaplan-Meier and Cox proportional hazards. Analyses were stratified by treatment line (first line/salvage) and included multivariable models adjusting for known prognostic factors. Results: A total of 1026 patients with aUC were identified; 614, 617, and 638 were included in ORR, OS, PFS analyses, respectively. Overall, 150 pts had history of prior intravesical BCG treatment. ORR to ICI was similar between those with and without prior intravesical BCG exposure in both first line and salvage settings (adjusted odds radios 0.55 [P= .08] and 1.65 [P= .12]). OS (adjusted hazard ratios 1.05 [P= .79] and 1.13 [P= .49]) and PFS (adjusted hazard ratios 1.12 [P= .55] and 0.87 [P= .39]) were similar between those with and without intravesical BCG exposure in first line and salvage settings. Conclusion: Prior intravesical BCG was not associated with differences in response and survival in patients with aUC treated with ICI. Limitations include retrospective nature, lack of randomization, presence of selection and confounding biases. This study provides important preliminary data that prior intravesical BCG exposure may not impact ICI efficacy in aUC. © 2021

Published
2022

28. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes

Author

Esagian, S.M. Khaki, A.R. Diamantopoulos, L.N. Carril-Ajuria, L. Castellano, D. De Kouchkovsky, I. Park, J.J. Alva, A. Bilen, M.A. Stewart, T.F. McKay, R.R. Santos, V.S. Agarwal, N. Jain, J. Zakharia, Y. Morales-Barrera, R. Devitt, M.E. Nelson, A. Hoimes, C.J. Shreck, E. Gartrell, B.A. Sankin, A. Tripathi, A. Zakopoulou, R. Bamias, A. Rodriguez-Vida, A. Drakaki, A. Liu, S. Kumar, V. Lythgoe, M.P. Pinato, D.J. Murgic, J. Fröbe, A. Joshi, M. Isaacsson Velho, P. Hahn, N. Alonso Buznego, L. Duran, I. Moses, M. Barata, P. Galsky, M.D. Sonpavde, G. Yu, E.Y. Msaouel, P. Koshkin, V.S. Grivas, P.

Abstract

Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and Methods: We performed a retrospective cohort study collecting clinicopathological, treatment, and outcome data for patients with aUC receiving ICIs from 2013 to 2020 across 24 institutions. We compared the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) between patients with upper and lower tract UC (UTUC, LTUC). Uni- and multivariable logistic and Cox regression were used to assess the effect of UTUC on ORR, OS, and PFS. Subgroup analyses were performed stratified based on histology (pure, mixed) and line of treatment (first line, subsequent line). Results: Out of a total of 746 eligible patients, 707, 717, and 738 were included in the ORR, OS, and PFS analyses, respectively. Our results did not contradict the hypothesis that patients with UTUC and LTUC had similar ORRs (24% vs 28%; adjusted odds ratio [aOR] 0.73, 95% confidence interval [CI] 0.43–1.24), OS (median 9.8 vs 9.6 months; adjusted hazard ratio [aHR] 0.93, 95% CI 0.73–1.19), and PFS (median 4.3 vs 4.1 months; aHR 1.01, 95% CI 0.81–1.27). Patients with mixed-histology UTUC had a significantly lower ORR and shorter PFS vs mixed-histology LTUC (aOR 0.20, 95% CI 0.05–0.91 and aHR 1.66, 95% CI 1.06–2.59), respectively). Conclusion: Overall, patients with UTUC and LTUC receiving ICIs have comparable treatment response and outcomes. Subgroup analyses based on histology showed that those with mixed-histology UTUC had a lower ORR and shorter PFS compared to mixed-histology LTUC. Further studies and evaluation of molecular biomarkers can help refine patient selection for immunotherapy. © 2021 The Authors BJU International © 2021 BJU International Published by John Wiley & Sons Ltd

Published
2021

40. Assessing quality of life in Australian patients with Graves' ophthalmopathy

Author

Park, J.J., Sullivan, T.J., Mortimer, R.H., Wagenaar, M., and Perry-Keene, D.A.

Subjects
Thyroid eye disease -- Research -- Care and treatment, Health, Care and treatment, Research
Abstract

Br J Ophthalmol 2004;88:75-78 Aims: To determine quality of life and adequacy of education and counselling in Australian patients with Graves' ophthalmopathy during the course of their illness. Methods: A [...]

Published
2004

41. 771P Efficacy of enfortumab vedotin in populations of interest among patients with advanced urothelial cancer

Author

Koshkin, V.S., primary, Sun, Y., additional, Osterman, C.K., additional, Natesan, D., additional, Su, C., additional, Lemke, E., additional, Khaki, A.R., additional, Johnson, A., additional, Owens, X., additional, Park, J.J., additional, Basu, A., additional, Coelho Barata, P.M., additional, Davis, N., additional, Grivas, P., additional, Milowsky, M., additional, Kilari, D., additional, and Alva, A., additional

Published
2020
Full Text
View/download PDF

42. 417P Lymph node (LN) retrieval as a high-risk factor in stage II and III colon cancer

Author

Kim, Y.T., primary, Kim, H.S., additional, Shin, S.J., additional, Beom, S-H., additional, Kim, N.K., additional, Lee, K.Y., additional, Min, B.S., additional, Hur, H., additional, Cho, M.S., additional, Han, Y.D., additional, Yang, S.Y., additional, Koom, W.S., additional, Chang, J.S., additional, Kim, T.I., additional, Cheon, J.H., additional, Park, S.J., additional, Park, J.J., additional, Seo, N.E., additional, Lim, J.S., additional, and Ahn, J.B., additional

Published
2020
Full Text
View/download PDF

46. Newsletter of the Russian Society of Nematologist

Author

ANIKIEVA, L.V., BESPYATOVA, L.A., BUGMYRIN, S.V., SPIRIDONOV, S.E., BUTENKO, K.O., KOROBUSHKIN D.I, GONGALSKY, K.B., SAIFUTDINOV, R.A., SHESTEPEROV, A.A., ZAITSEV, A.S., CLAEYS M, HANDAYANI, N.D., LESTARI, P., YUSHIN, V.V., DIKIN A, HELDERS J, BERT, W., FABIYI, O.A., OLATUNJI, G.A., IESHKO E.P, NIKONOROVA, I.A., KHUSAINOV R.V., KUDRIN A.A, KONAKOVA T.N, TASKAEVA, A.A., KOLESNIKOVA A.A., LEBEDEVA, D.I., YAKOVLEVA G.A., LEE D.W, OKKI M.A, NA H.B, AHN H, KIM H, CHOI I, CHOI Y, PARK, J.J., KABIR M.F, MALYSHEVA, S.V., EFEIKIN, B.D., MATVEEVA, E.M., BESPYATOVA L.А., BUGMYRIN S.V, SUSHCHUK, A.A., SEIML-BUHINGER, V.V., PAVLOVA, T.V., MARTJANOV, R.S., PROTASOV, Y.G., YURKEVICH M.G, SIDOROVA V.V., DUBROVINA, I.A., MILOVANKINA A.A, FADEEVA N.P, MORDUKHOVICH, V.V., SEMENCHENKO, A.A., ZOGRAF J.K, NAUMOVA, T.V., GAGARIN, V.G., IESHKO E.P., ODOYEVSKAYA, I.M., SEREDKIN, I.V., KUDRYASHOVA, I.B., KURNOSOVA, O.P., REKSTINA, V.V., RUDENSKAYA, Y.A., ZIGANSHIN, R.H., KALEBINA, T.S., PERRY R.N., POLYANINA, K.S., RYSS A.YU., POPOV, I.O., POPOVA, E.N., KOUKHTA, A.E., PRIDANNIKOV, M.V., UKOLOVA, A.Y., SINKEVICH O.V, LYABZINA, S.N., EVSTRATOVA, L.P., BEZERRA, T.N., DECRAEMER W, EISENDLE-FLOCKNER U, HOLOVACHOV, O., SANTIAGO, R.P., LEDUC, D., MILJUTIN D, SHARMA J, TCHESUNOV A.V, MOKIEVSKY V.O, VENEKEY V, ZHAO Z, HODDA M, VANREUSEL, A., KRIVOROT I.V, TABOLIN, S.B., TIKHOMIROVA, N.D., TREBUKHOVA YU.A, PAVLYUK O.N, LUTAENKO K.A, LI BAOQUAN, BO SONG, TSKITISHVILI, E.T., JGENTI, L.T., BAGATHURIA, N.L., TSKITISHVILI, T.D., GIGOLASHVILI, M.G., ELIAVA, I.J., UDALOVA ZH.V., GINS, M.S., GINS, V.K., ZINOVIEVA, S.V., GLIZNUTSA, L.A., and SOKOLOVA E.A

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results